GlassScriptPhysician profile
Etienne Kenfack
NPI 1033677679
$2,118.65
in general payments reported to CMS, 2019-2025
17 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.58 · 2022: $272 · 2023: $227 · 2024: $551 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.74 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $586.51 | 2023-2025 | Relistor |
| Protega Pharmaceutials INC | $477.05 | 2022-2025 | Roxybond |
| Scilex Pharmaceuticals INC. | $431.76 | 2022-2025 | Ztlido |
| Forte Bio-Pharma LLC | $148.86 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Vertex Pharmaceuticals Incorporated | $61.07 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $57.03 | 2022 | |
| Vertos Medical, INC. | $55.72 | 2024 | Mild Device Kit |
| Medtronic, INC. | $50.87 | 2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $49.58 | 2021 | |
| Relievant Medsystems, INC. | $37.06 | 2022 | |
| Valinor Pharma, LLC | $36.26 | 2025 | Movantik |
| Pacira Pharmaceuticals Incorporated | $35.43 | 2022 | |
| Ibsa Pharma INC. | $29.25 | 2023-2024 | Tirosint, Licart, Licart |
| Averitas Pharma INC. | $16.70 | 2025 | Qutenza |
| Si-Bone, INC. | $15.93 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.82 | 2022 | |
| Allergan, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Etienne Kenfack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.